HomeCompareAQUA vs PFE

AQUA vs PFE: Dividend Comparison 2026

AQUA yields 4.01% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $23.6K in total portfolio value· pulled ahead in Year 9
10 years
AQUA
AQUA
● Live price
4.01%
Share price
$49.88
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.0K
Annual income
$518.67
Full AQUA calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AQUA vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQUAPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQUA + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AQUA pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQUA
Annual income on $10K today (after 15% tax)
$340.82/yr
After 10yr DRIP, annual income (after tax)
$440.87/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,879.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQUA + PFE for your $10,000?

AQUA: 50%PFE: 50%
100% PFE50/50100% AQUA
Portfolio after 10yr
$37.8K
Annual income
$13,388.70/yr
Blended yield
35.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AQUA
Analyst Ratings
6
Buy
9
Hold
Consensus: Hold
Price Target
$50.50
+1.2% upside vs current
Range: $50.00 — $52.00
Altman Z
3.9
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQUA buys
10
PFE buys
0
PoliticianChamberTickerTypeAmountDate
Susie Lee🏢 House$AQUA▼ Sell$15,001 - $50,0002023-05-09
Susie Lee🏢 House$AQUA▲ Buy$1,001 - $15,0002021-09-24
Susie Lee🏢 House$AQUA▲ Buy$1,001 - $15,0002021-02-18
Susie Lee🏢 House$AQUA▲ Buy$1,001 - $15,0002020-03-06
Greg Gianforte🏢 House$AQUA▼ Sell$50,001 - $100,0002020-02-11
Greg Gianforte🏢 House$AQUA▼ Sell$50,001 - $100,0002020-02-10
Greg Gianforte🏢 House$AQUA▲ Buy$15,001 - $50,0002018-11-05
Greg Gianforte🏢 House$AQUA▲ Buy$15,001 - $50,0002018-10-23
Greg Gianforte🏢 House$AQUA▲ Buy$15,001 - $50,0002018-10-22
Greg Gianforte🏢 House$AQUA▲ Buy$15,001 - $50,0002018-08-28
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQUAPFE
Forward yield4.01%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$26.0K$49.6K
Annual income after 10y$518.67$26,258.71
Total dividends collected$4.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold
Analyst price target$50.50$27.50

Year-by-year: AQUA vs PFE ($10,000, DRIP)

YearAQUA PortfolioAQUA Income/yrPFE PortfolioPFE Income/yrGap
1$11,101$400.96$9,153$693.39+$1.9KAQUA
2$12,294$415.99$8,593$849.25+$3.7KAQUA
3$13,585$430.56$8,336$1,066.78+$5.2KAQUA
4$14,981$444.65$8,437$1,384.80+$6.5KAQUA
5$16,488$458.25$9,013$1,875.40+$7.5KAQUA
6$18,113$471.35$10,306$2,680.72+$7.8KAQUA
7$19,865$483.94$12,820$4,101.38+$7.0KAQUA
8$21,752$496.03$17,673$6,826.70+$4.1KAQUA
9← crossover$23,782$507.60$27,543$12,591.86$3.8KPFE
10$25,965$518.67$49,560$26,258.71$23.6KPFE

AQUA vs PFE: Complete Analysis 2026

AQUAStock

Evoqua Water Technologies Corp. provides water and wastewater treatment systems and technologies, and mobile and emergency water supply solutions and contract services for industrial, commercial, and municipal water treatment markets in the United States and internationally. It operates in two segments, Integrated Solutions and Services, and Applied Product Technologies. The Integrated Solutions and Services segment offers capital systems and related recurring aftermarket services, parts, and consumables, as well as long-term and short-term service contracts, and emergency services for treating process water, utility water, and wastewater. This segment also provides odor and corrosion control services and drinking water treatment systems for municipalities. It serves manufacturing, healthcare, pharmaceuticals, biotech, power, microelectronics, chemical processing, food and beverage, and refining industries. The Applied Product Technologies segment offers advanced filtration and separation products, such as VAF self-cleaning filters, Ionpure electrodeionization systems, and Vortisand filtration systems, as well as filter presses and related consumables, and aftermarket products for customers in the microelectronics, pharmaceutical, and power end markets. It also offers disinfection solutions, including chemical and non-chemical disinfection technologies comprising low and medium pressure ultraviolet, ozone, onsite hypochlorite generation, and chlorine and chlorine dioxide systems for municipal drinking water, industrial, light manufacturing, commercial, and aquatics markets. In addition, this segment offers wastewater technologies, including biological treatment, clarification, filtration, nutrient removal, biosolid, and field-erected biological wastewater treatment plant solutions. Further, it offers aquatics and electrochlorination solutions. The company was incorporated in 2013 and is headquartered in Pittsburgh, Pennsylvania.

Full AQUA Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AQUA vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQUA vs SCHDAQUA vs JEPIAQUA vs OAQUA vs KOAQUA vs MAINAQUA vs JNJAQUA vs MRKAQUA vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.